The role of three major Ras downstream effector pathways in the induction of mammary cancer was studied using an in situ mammary ductal gene delivery model. Replicationdefective retroviral vectors were used to infect endogenous rat mammary epithelial cells with three individual Ras effector loop mutants, each of which transduces its signal through a different Ras effector pathway (Raf, PI3K or RalGDS). Several groups have used Ras effector loop mutants in cultured cells, clearly characterizing the signaling specificity of each over a wide range of cell lines and conditions. Each of the three Ras effector loop mutations impairs Ras for neoplastic transformation of immortal cell lines in culture. In contrast, when evaluated in vivo by infecting endogenous rat mammary epithelial cells in situ with retroviral vectors, we find that codon 12 mutant activated V12-Ras and all three V12-Ras effector loop mutants individually induce mammary carcinomas. Most notably, a Ras effector loop mutant that lacks affinity with PI3K and RalGDS but retains affinity with Raf (E38-V12-Ras) is relatively similar in potency to V12-Ras for mammary carcinoma induction. Two other Ras effector loop mutants, each lacking affinity with Raf, one retaining affinity with PI3K (C40-V12-Ras), the other with RalGDS (G37-V12-Ras), resulted in much longer tumor latency than E38-V12-Ras and V12-Ras and a reduced carcinoma frequency. Tumor latencies for V12-Ras, E38-V12-Ras, C40-V12-Ras and G37-V12-Ras were 4, 4, 11 and 12 weeks, respectively. We conclude that the Ras-Raf pathway can function independently of the Ras-PI3K and Ras-RalGDS pathways for rapid induction of rat mammary carcinomas, while Ras-PI3K and Ras-RalGDS pathways may also individually induce mammary carcinomas following a long latency.
Introduction
Activation of Ras is one of the most common molecular events in the etiology of human cancer. This makes Ras an important and heavily researched target for the prevention and treatment of cancer. However, Ras is also involved as a master switch in many normal physiologic functions, increasing the likelihood that inhibiting Ras will lead to systemic toxicity. Cell culture models and biochemical studies have shown that activated Ras Abbreviations: P13K, phosphotydalinositol-3-kinase; Ras GAP; Ras GTPase activating protein; Ras GDS; Ras guanine nucleotide dissociation stimulator.
proteins interact directly with several effector proteins, which then induce cellular responses. Targeting the Ras effector pathway(s) that are key to carcinogenesis may minimize drug toxicity, improving the therapeutic index. For these reasons it is important to determine which Ras effector(s) are critical to carcinogenesis. Cell culture models indicate that a minimum of three Ras effector pathways make contributions to carcinogenesis. In vitro studies with Ras effector loop mutants are extended here to an in vivo epithelial cell model, which more accurately emulates the human disease. In this study we investigate which Ras downstream effectors are important for neoplastic transformation of endogenous rat mammary epithelial cells in situ. These cells have never been exposed to the mutating effects of cell culture, or to selection for the low frequency immortal cells from which cell lines historically proceed. Our data are consistent with data from cell lines, suggesting that at least three different Ras effectors contribute to neoplastic transformation. However, induction of rat mammary carcinomas by expression of Ras effector loop mutants in vivo is more potent than expected based on cell culture models.
The Ras genes were some of the earliest characterized oncogenes (1, 2) . Substantial in vitro data have allowed the elucidation of mechanisms of transformation in culture (3) (4) (5) (6) , and many of these findings also apply when cell lines transformed by Ras effector loop mutants in culture are transferred to in vivo environments (4, 7, 8) . However, mechanistic in vivo data from endogenous epithelial cells, regarding Ras-induced carcinogenesis, has been unavailable. Activation of Ras is a necessary intermediate for signal propagation from most growth factor receptors (9, 12 ), yet several other extracellular stimuli also lead to Ras activation (13) (14) (15) (16) . Ras activity also has several cellular effects, including mitosis, differentiation (17) (18) (19) and apoptosis (20) (21) (22) . How Ras signaling activity is regulated to create different cellular responses is unclear. Several cellular proteins have been proposed as Ras downstream effectors. One-way Ras activity could lead to different effects is by modulating activation of different downstream effectors.
Normal Ras proteins cycle between active and inactive states. Various stimuli activate Ras by facilitating its interaction with a Ras guanine nucleotide dissociation stimulator (RasGDS), stimulating release of GDP, which allows binding to GTP. Binding to GTP alters the conformation of the Ras effector loop, greatly increasing its affinity with effector proteins [including Raf (23) (24) (25) (26) (27) , phosphotydalinositol-3-kinase (PI3K) (28, 29) and RalGDS (30) (31) (32) ]. Ras GTPase activating protein (Ras GAP) is also an effector (33) (34) (35) (36) (37) (38) , but it is best characterized as a down-regulator of Ras (39, 40) . Interaction with Ras GAP increases the intrinsic GTPase activity of Ras by several orders of magnitude, resulting in hydrolysis of bound GTP to GDP, deactivating Ras. Most coding mutations in codon 12 (i.e. V12, E12, etc.) of Ras prevent GTP hydrolysis, resulting in constitutively active Ras.
With the discovery of many effector proteins, the question of which effector(s) elicit the oncogenic effect of Ras is important. Several researchers have probed this question with Ras effector loop mutants, characterizing them well in vitro and in several cell lines (3) (4) (5) (6) (7) (8) . Mutations in the effector loop of Ras have been shown to greatly reduce the affinity of Ras with its effector proteins. Some of these Ras effector loop mutants are selective, greatly reducing affinity with most effectors yet retaining a significant affinity with select effectors. For instance, mutation from glu to gly in codon 37 (G37-V12-Ras) greatly reduces affinity with Raf and PI3K but retains affinity with RalGDS. In contrast, mutation from asp to glu in codon 38 (E38-V12-Ras) retains affinity with Raf but lacks affinity with RalGDS and PI3K. Complementing these, mutation from tyr to cys in codon 40 (C40-V12-Ras) retains affinity with PI3K but not with RalGDS or Raf. These three Ras effector loop mutants retain affinity with RasGAP, but still allow investigation of the separate contributions that Raf, PI3K and RalGDS make to neoplastic transformation induced by Ras. Multiple groups have characterized Ras effector loop mutants in cultured cells, clearly demonstrating the signaling specificity of each. The importance of synergy between multiple Ras effectors for efficient transformation of cultured cells is a common theme in several studies.
Mutations in the effector loop of Ras substantially attenuate transformation of cultured NIH 3T3 fibroblasts (3, 4) . However, any pair of Ras effector loop mutants signaling through different effectors synergistically transform 3T3 cell lines (3, 4) . This suggests that synergy between multiple Ras effectors is necessary for efficient neoplastic transformation. However, NIH 3T3 cell lines transformed by expressing Ras effector loop mutants individually form tumors when injected into nude mice (4) . Fibroblasts expressing V12-G37-Ras or V12-C40-Ras take twice as long to form tumors, thus lack of affinity with Raf can reduce the tumor growth rate from transplanted fibroblasts in nude mice (4) . Furthermore, subcutaneous tumors from 3T3s expressing V12-G37-Ras or V12-C40-Ras are deficient for metastasis to the lung in nude mice (7) . In contrast, others have found that 3T3 cells transformed by V12-G37-Ras (but not C40-V12-Ras) efficiently metastasize to the lung from tail vein injection, although this also seems partially dependent on Erk (the primary effector of Raf-MEKErk signal transduction) since it can be inhibited by PAC1 (8) . In fibroblasts, individual Ras effector loop mutants have diminished transformation efficiency in comparison with activated Ras, but Raf appears to be a more potent oncogenic effector than PI3K or RalGDS.
Approximately 85% of human tumors originate from epithelial cells, so it is important to test Ras effector loop mutants in epithelial cells. Lack of an appropriate extracellular matrix frequently induces apoptosis in normal epithelial cells; this suspension-induced apoptosis is referred to as anoikis. Immortalized RIE-1 rat intestinal epithelial cell lines or ROSE 199 rat ovarian surface epithelial cell lines are resistant to anoikis when expressing V12-Ras, but are not resistant to anoikis when expressing individual Ras effector loop mutants (5) . Anoikis resistance in these cells seems to require Raf activity, but Raf activation is not sufficient for resistance (5) . In contrast, the MDCK epithelial cell line is resistant to anoikis when expressing V12-Ras or V12-C40-Ras, suggesting PI3K activity is sufficient to protect MDCK epithelial cells from anoikis (6) . Contrasting this is increased in vitro invasiveness induced by G37-V12-Ras in 3T3 fibroblast, MCF10A immortalized breast 100 epithelial cells, and NMuNg mammary cancer epithelial cells (8) . As with fibroblasts, epithelial cell lines in culture generally tend to require synergy between multiple effectors. However, unlike cultured fibroblasts where none of these individual effectors seems necessary or sufficient for efficient transformation, in cultured epithelial cells individual pathways appear to be necessary and occasionally sufficient. The next step for extending the data is to evaluate Ras effector loop mutants in vivo, with endogenous epithelial cells.
Delivery of Ras effector loop mutants into endogenous epithelial cells in situ using replication-defective retroviral vectors infused into the central mammary duct provides a good in vivo model for characterization of Ras in the context of mammary carcinogenesis (41) . This somatic cell approach has advantages over transgenic models. Retroviral infusion into milk ducts anatomically targets expression to individual cells, driving expression with a constitutive retroviral promoter. This is in contrast to mammary transgenic models that rely on physiological targeting with hormonally responsive promoters. The hormonal stimulus that drives mammary targeting promoters, such as WAP or MMTV, can confound the results of Ras-driven transformation studies, since steroid hormones that drive these promotors also modulate the multistage process of mammary carcinogenesis. In addition, integration positional effects have the potential to modulate observations from transgenic rodents. In contrast, each infused mammary gland contains thousands of infected cells with a random distribution of integration sites between cells. Finally, the low rate of infection in this infusion model (Ͻ0.5% of total mammary epithelial cells) allows infected cells to be surrounded by normal cells, as is not the case with germ line transgenic models. As cancer is a clonal disease, it is advantageous to model it in a way that altered cells are surrounded by normal cells. Unfortunately this also makes biochemical characterizations of infected cells difficult until after carcinogenic selection has occurred. We have used this retroviral infusion model system to express three Ras effector loop mutants in vivo in order to assess the role of Ras-Raf, Ras-PI3K and Ras-RalGDS signal transduction pathways in mammary carcinogenesis. We find that each of these activated Ras effector loop mutant proteins can yield mammary carcinomas from infused glands with varying efficiency.
Methods

Vector construction
Ras effector loop mutant cDNAs were kindly provided by Dr Julian Downward (3). From these templates, PCR products were generated for V12-Ras and the three V12-Ras effector loop mutants. The 5Ј primer (aaaagcggccgccatgacagaatacaaacttgtgg) contains a NotI site, Kozac consensus sequence, and sequence complementing the first few codons of H-Ras. The 3Ј primer (aaaactcgagtcaggacagcacacactt) contains an XhoI site and sequence complementing the area surrounding the Ras stop codon. These four PCR products were subcloned into the JR plasmid (41) by standard procedures. After subcloning, the cDNA sequences were confirmed prior to transfection. These constructs are all identical with the exception of the effector loop mutations.
Retroviral vector preparation and culture conditions
Cell lines were maintained in DMEM (prepared with 20% of the recommended bicarbonate) containing 25 mM HEPES, 10% FBS and gentamycin. The ecotropic packaging cell line Psi-CRE was transfected with JR plasmid DNA by a lipofectamine protocol (Life Technologies, Rockville, MD). Ecotropic retrovirus was harvested 2 days later and used with 5 µg/ml polybrene to infect the amphotropic packaging cell line PA317. Infected PA317 cells were selected by 10-12 days growth in 0.4 mg/ml G418 (Life Technologies). Resistant colonies were cloned and expanded. Supernatant from expanded clones was titered for virus on 3T3 cells. High-titer clones for each retroviral at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from vector were tested for the presence of helper virus. A helper virus-free, hightiter (Ͼ10 5 c.f.u./ml) clone for each Ras construct was further expanded. Two days preceding virus concentration, the temperature was lowered to 33°C to improve viral stability, thus increasing titer. Virus was pelleted by centrifugation at 34 000 g for 2 h through 20% sucrose. The pellets were resuspended in 1/100 original volume of DMEM, then stored at -80°C. High-titer stocks (Ͼ1ϫ10 7 c.f.u./ml) were combined, titered and diluted appropriately for infusions.
Retroviral titer and helper virus test
Virus was titered by infecting 3T3 cells with diluted viral stocks using 5 µg/ml polybrene, and then these cells were split 2 days later into media containing 0.4 mg/ml G418 for selection. The number of G418 resistant colonies was counted 10-12 days later and the resulting counts were used to estimate the original undiluted viral stock concentrations. To test for helper virus, fresh media was put on infected G418-selected 3T3 cells and the supernatant was used with polybrene 48 h later to attempt infection of fresh 3T3 cells. G418 selection was added 2 days later and a lack of G418 resistant clones suggests an absence of helper virus.
3T3 transformation assay
Highly contact-inhibited Swiss 3T3 cells were maintained at very low density. At the time of cell-cell contact, 3T3 cells from multiple plates were mixed for uniformity to prepare plates of cells for infection. Two days later, just prior to infection, cells were harvested from several plates to determine the number of cells per plate (~200 000). Previously titered retroviral concentrates were thawed and diluted to equal titers, then serially diluted to 5ϫ10 5 and 2.5ϫ10 4 G418 r c.f.u./ml retroviral stocks. For combined viral infections, equal amounts of diluted stocks were mixed prior to infection, maintaining 5ϫ10 5 G418 r c.f.u./ml while diluting each vector 2-fold. Diluted stocks (2, 10, 16 and 60 µl) were added with 5 µg/ml polybrene to infect 3T3 cells. Twelve days later each plate was scored for the number of cell colonies with stacked nuclei.
Rat infusion and follow up
Rats were maintained with food and water available ad libitum, in temperatureand humidity-controlled facilities on a 12 h light/dark cycle. Virgin female Wistar-Furth (Harlan Sprague-Dawley) rats, 50-60 days of age, were used. Retroviral vectors were infused into the central duct of each of 12 mammary glands for each rat. One microliter of 8 mg/ml polybrene (to improve infection) and 1 µl of 20 mg/ml fast green (for visualizing infusion) were added per 100 µl thawed viral suspension immediately before infusion. Rats were anesthetized and the central duct of each gland was cannulated with a 27-gauge blunt-ended needle and infused with about 15 µl of viral suspension. Rats were palpated weekly for tumors following infusion, with size estimates of palpable tumors recorded for each gland. Moribund rats and those that remained at the end of the experiment were necropsied. Tumor samples were fixed in Omni fixative and embedded in paraffin for sectioning and hematoxylin and eosin staining.
Statistical methods
The effect of virus type on the number of positive glands per animal at 7 and 15 weeks was assessed using a generalized linear model assuming Poisson variability. The log-rank test was used to test for an effect of virus type on the time to first tumor. Tests for pairwise differences were performed using similar methods when a significant overall effect of virus was found.
The effect of virus on the growth pattern of the tumors was also assessed. The tumor sizes recorded at the time of each tumor's initial palpation, and the tumor sizes recorded during each of the following 2 weeks, were analyzed without regard for the calendar week in which each tumor first appeared. At each of the three time points, a one-way analysis of variance was used to test for the effect of virus after transforming the tumor sizes to the log scale.
Results
Cell culture results with retroviral vectors are consistent with published results (3,4) from plasmid transfection experiments: all three individual mutations in the Ras effector loop attenuate Ras transformation of cultured 3T3 fibroblasts. We find that neoplastic transformation is induced with nearly 100% penetrance in highly contact-inhibited Swiss 3T3 cells by a single retroviral integration expressing V12-Ras ( Figure 1F ). Foci from V12-Ras infected 3T3 cells became visible to the naked eye within 8 days after infection (confirmed through phasecontrast microscopy) and had frequently divided into foci clusters by day 12 post-infection ( Figure 1A ). Retroviral infection with E38-V12-Ras resulted in 3T3 transformation at one-fifth the frequency of V12-Ras ( Figure 1C and F) , which is more frequent than expected based on plasmid transfection experiments (3, 4) . The rate of foci formation induced by C40-V12-Ras and G37-V12-Ras expression (0.10 and 0.05% of infected cells, respectively, Figure 1D -F) is comparable with plasmid transfection experiments (3, 4) . While C40-V12-Ras and G37-V12-Ras rarely induced foci, they did reduce contact inhibition increasing terminal cellular density, and at higher MOIs shortened the time to confluence.
Any pair of the three V12-Ras effector loop mutants is synergistic for fibroblast transformation (3, 4) . Synergy between C40-V12-Ras and G37-V12-Ras is quantifiable if we assume Poisson distribution for co-infection. Ten percent of Swiss 3T3 cells co-infected with C40-V12-Ras and G37-V12-Ras form foci ( Figure 1F ) (the number of foci expected from individual infections was subtracted from the total foci count to estimate the number of foci resulting from co-infection). Transformation from C40-V12-Ras and G37-V12-Ras co-infection is 100 times more frequent than either individually. Individual infections greatly outnumber co-infections, so the high frequency of transformation by E38-V12-Ras infection prevented quantification of E38-V12-Ras synergy with C40-V12-Ras or G37-V12-Ras. Somewhat like our cell culture results, each of the described Ras effector loop mutants is individually capable of inducing in situ rat mammary gland carcinogenesis (Figures 2 and 3) . Most notably, the latency of tumor formation resulting from expression of E38-V12-Ras is not significantly different from V12-Ras tumorigenesis (P ϭ 0.0544). With viral titers of 1.6 ϫ10 7 Ϯ 0.3 ϫ10 7 c.f.u./ml, more than half of the rats develop a palpable tumor by the fourth or fifth weeks after Fig. 3 . Latency and frequency of mammary tumor induction from in situ expression of G37-V12-Ras, C40-V12-Ras, and E38-V12-Ras. (A) Latency to palpable carcinoma induction by E38-V12-Ras is significantly less (P Ͻ 0.0001) than for C40-V12-Ras or for G37-V12-Ras. Latency to palpable carcinoma induction by C40-V12-Ras is not significantly different (P ϭ 0.2547) from G37-V12-Ras. (B) Mean frequency per rat of palpable carcinoma induction by E38-V12-Ras is significantly greater (P Ͻ 0.0001) than C40-V12-Ras or G37-V12-Ras. There is a small but significant (P ϭ 0.0265) difference between the mean frequency per rat of carcinoma induction by C40-V12-Ras and by G37-V12-Ras. β-galactosidase vector does not induce mammary carcinomas. For each vector 12 rats were infused with 15 µl of high titer retroviral suspension (5 ϫ 10 7 Ϯ 1.1 ϫ 10 7 , 6 ϫ 10 7 Ϯ 0.3 ϫ 10 7 and 7 ϫ 10 7 Ϯ 2 ϫ 10 7 c.f.u./ml for G37-V12-Ras, C40-V12-Ras and E38-V12-Ras, respectively) into each of 12 glands, 144 glands with each vector. Location and diameter estimates of all palpable mammary tumors Ͼ3 mm were recorded weekly.
infusion of V12-Ras or E38-V12-Ras vectors respectively (Figure 2A ). In contrast, the frequency of tumor formation following infusion with E38-V12-Ras is~55% of that obtained with V12-Ras (P Ͻ 0.0001) ( Figure 2B ).
Even at high titers (Ͼ5ϫ10 7 c.f.u./ml), it takes 11-12 weeks after infusion with either C40-V12-Ras or G37-V12-Ras before 50% of rats develop a single palpable tumor ( Figure 3A) . At a similar titer, Ͼ80% of rats infused with E38-V12-Ras have tumor(s) by the fourth week after infusion ( Figure 3A) . With C40-V12-Ras or G37-V12-Ras, the appearance of additional palpable tumors is delayed and distributed over a longer time period following detection of the first palpable tumor ( Figure 3B ). Expression of β-galactosidase from the same retroviral vector backbone does not cause mammary tumors (41) . Negative control rats infused with a β-galactosidase expression vector, were followed for over 18 months, with no detectable tumors ( Figure 3B , and data not shown). Carcino- Fig. 4 . Mean palpated diameters of mammary carcinomas induced by in situ expression of E38-V12-Ras, C40-V12-Ras and G37-V12-Ras effector loop mutants over the first 2 weeks following detection. The tumor diameters recorded at the time of each tumor's initial palpation, and the tumor diameters recorded during each of the following 2 weeks, were analyzed without regard for the calendar week in which each tumor first appeared. Mean diameter of carcinomas at their first recorded palpation is~3.7 mm, regardless of the Ras vector infused (no significant difference, P ϭ 0.8607). There is also no significant difference in the mean diameter estimates of carcinomas from different Ras effector loop mutants the first (P ϭ 0.6504) and second (P ϭ 0.9686) weeks after initially palpable. All 144 glands of 12 rats were infused for each vector. Location and diameter estimates to the nearest mm of all palpable mammary tumors Ͼ3 mm were recorded weekly. Initial palpation diameter means include 62, 54 and 44 carcinomas induced by E38-V12-Ras, C40-V12-Ras and G37-V12-Ras, respectively. genesis from either of two Ras effector loop mutants that lack affinity with Raf, have long latencies in comparison with those from E38-V12-Ras, yet once initially palpable, individual tumor growth rates are comparable for all three Ras effector loop mutants (Figure 4) . Finally an average of five carcinomas from each effector loop mutant group were re-sequenced. No back mutations or other mutations were detected within the effector loops of these carcinomas (data not shown).
Histopathological evaluation reveals that the tumors generated by each vector are exclusively mammary carcinomas, with no consistently discernible histological differences between V12-Ras and V12-Ras effector loop mutant-carrying carcinomas. The great majority of these carcinomas were diagnosed as papillary in nature ( Figure 5) ; however, several cribriform carcinomas were also noted.
Discussion
Ras effects are signaled through several pathways including Raf, PI3K and RalGDS. In anticipation of investigating the individual capability of V12-Ras effector loop mutants to induce cancer in vivo using our retroviral mammary model, we first confirmed that our 3T3 transformation results from retroviral infection, are consistent with the published data using plasmid transfection (3). Transformation of cultured 3T3 fibroblasts was attenuated by all three V12-Ras effector loop mutants. The very low frequency of 3T3 transformation induced by C40-V12-Ras and G37-V12-Ras, when compared with V12-Ras is in agreement with the published data using plasmid transfection.
The low frequency of 3T3 transformation by C40-V12-Ras and G37-V12-Ras individually allows a rough quantification of the synergy between the two. It is important to note that the 100-fold increase is a high estimate. While care was taken to assure thorough mixing of vectors in the infecting media, ideal Poisson distribution is unattainable. Less than ideal distribution would increase the number of co-infections and presumably foci, causing a high estimate of transformation frequency induced by co-infection. The rough synergy estimate also assumes the synergistic activities must be contained within a given cell. If paracrine synergy induced extra foci from singly infected cells, this would also contribute to a high estimate of synergy induced by co-infection.
The frequency of neoplastic transformation induced in Swiss 3T3 cells by retroviral infection with E38-V12-Ras is higher than expected based on published plasmid transfection experiments (3, 4) . Published plasmid transfection experiments with 3T3 cells rely on S35-V12-Ras for Raf specific signaling. S35-V12-Ras has been shown to retain some residual affinity for RalGDS, and also retains less residual affinity for Raf than at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from E38-V12-Ras (3). These were the reasons for our choosing E38-V12-Ras over S35-V12-Ras, and may also account for the increased frequency of foci formation in 3T3 cells. The low passage highly contact-inhibited Swiss 3T3 used here could also be more sensitive to transformation by Raf than the 3T3 strains that were used in plasmid transfection experiments (3, 4) . However, we have found that the rate of transformation from infection with N-terminal truncated Raf (∆-Raf, manuscript in preparation) conforms very well to published results from plasmid transfection experiments (3) . While the frequency of neoplastic transformation in 3T3 cells from E38-V12-Ras was higher than expected, it was nonetheless clearly attenuated. In addition to having only one-fifth the penetrance of V12-Ras in 3T3 cells, foci induced by E38-V12-Ras were less prone to becoming clusters of foci.
In partial contrast to results in culture, V12-Ras and all three V12-Ras effector loop mutants efficiently induce carcinomas in the rat mammary gland. Most notably, mammary carcinoma latency and morphology from E38-V12-Ras are not significantly different from those induced by V12-Ras. The multiplicity of carcinoma induction by E38-V12-Ras is about half as frequent as that induced by V12-Ras. As E38-V12-Ras retains Ͻ40% of its affinity with Raf (3), one might expect attenuated transformation, even if Raf were the only oncogenic effector of Ras. However, Ras effectors compete for the effector loop of V12-Ras, so reduced competitive inhibition with PI3K and RalGDS for the E38-V12-Ras effector loop may compensate for reduced affinity with Raf. Furthermore, competitive inhibition between E38-V12-Ras and endogenous Ras for the downregulator RasGAP could increase endogenous Ras activity, providing low level PI3K and/or RalGDS activity, with which high Raf activity may act synergistically. Regardless of competitive inhibition possibilities, our in vivo E38-V12-Ras data suggest that Raf is the primary oncogenic effector of Ras and that PI3K and RalGDS make at most a limited contribution to Ras transformation of mammary epithelial cells in situ. We have recently confirmed the ability of Raf activation to induce rat mammary carcinomas with in situ expression of ∆-Raf (manuscript in preparation). Efficient carcinoma induction by E38-V12-Ras suggest major anticancer effects could be obtained by targeting the Ras-Raf pathway, and that targeting PI3K and RalGDS without Raf is unlikely to treat activated Ras-containing tumors effectively.
Tumorigenesis from G37-V12-Ras or C40-V12-Ras has much greater latency than E38-V12-Ras and V12-Ras, emphasizing the importance of Raf for efficient and rapid transformation. There are several interpretations of what these results suggest regarding the role of PI3K and RalGDS in carcinogenesis. This may reflect additional independent oncogenic contributions from PI3K and RalGDS, which are unnecessary in the presence of sufficient Raf signal. However, as seen in this model with wt-H-Ras, deregulated overexpression itself may play a significant role in delayed transformation (42) . Deregulated over-expression could indirectly up-regulate endogenous Ras proteins by sequestering RasGAP, similar to the way dominant-negative Ras indirectly downregulates endogenous Ras proteins by sequestering RasGDS. Endogenous Ras might then provide Raf signaling sufficient for carcinogenesis. PI3K or RalGDS activity may also signal for increased Raf activity, for example through a Ras-PI3K-PKB-Rac-Pak3 pathway (43, 44) , so tumors from G37-V12-Ras or C40-V12-Ras expression might have high Raf activity. While V12-E38-Ras data suggest that Raf activity can be sufficient for rat mammary gland tumorigenesis, V12-G37-Ras and V12-C40-Ras data suggest Raf activity may not be necessary following long latency.
In summary, we find that Ras affinity with PI3K and RalGDS is unnecessary for rapid carcinogenesis from in situ rat mammary epithelial cells. Either of two Ras effector loop mutants that lack affinities with Raf were substantially impaired for their in vivo transformation ability. We conclude that Raf is the primary oncogenic effector of Ras, and Raf activation can initiate rat mammary gland carcinogenesis. Affinity of activated Ras with Raf is necessary and sufficient for rapid mammary gland carcinogenesis, while affinity with PI3K or RalGDS is sufficient for carcinogenesis after long latency. Our in vivo mammary epithelial cell data suggest that the Raf pathway may serve as the single most important pathway to target for the prevention and treatment of tumors containing active Ras.
